FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to hematology, and can be used for morphometric assessment of prediction of diffuse B-large-cell lymphoma (DBLCL). That is ensured by determining STAT3+ tumor cell count in the lymph nodes. Lymphadenectomy in histological sections of the lymphoid organ is followed by immunohistochemical staining and the relative number of STAT3+ tumor cells in the lymph node in % is measured morphometrically. If the relative number of STAT3+ tumor cells is less than 66 %, a favorable course of diffuse B-large-cell lymphoma is stated. If the disease is equal or more than 66 %, an unfavorable course of the disease is stated.
EFFECT: invention allows predicting the flow DBLCL in patients after lymphadenectomy.
1 cl, 3 ex
